| 3.59 -0.04 (-1.1%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.75 | 1-year : | 5.55 |
| Resists | First : | 4.07 | Second : | 4.75 |
| Pivot price | 3.32 |
|||
| Supports | First : | 3.43 | Second : | 3.03 |
| MAs | MA(5) : | 3.5 |
MA(20) : | 3.37  |
| MA(100) : | 4.94 |
MA(250) : | 8.36 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 73.9 |
D(3) : | 69.7 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 21.72 | Low : | 3.03 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ WVE ] has closed below upper band by 13.2%. Bollinger Bands are 23.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.7 - 3.72 | 3.72 - 3.74 |
| Low: | 3.38 - 3.41 | 3.41 - 3.43 |
| Close: | 3.55 - 3.59 | 3.59 - 3.62 |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Wed, 28 Oct 2026
Wave Life Sciences (WVE) Stock Rallies As Q3 Results Ease Loss Fears - Yahoo Finance
Wed, 28 Oct 2026
Wave Life Sciences (NasdaqGM:WVE) Stock Forecast & Analyst Predictions - Simply Wall St
Tue, 27 Oct 2026
Wave Life Sciences Ltd. Q3 2026 Earnings Call Summary - Yahoo Finance
Tue, 27 Oct 2026
Wave Life Sciences Ltd earnings beat by $0.02, revenue topped estimates - Investing.com
Tue, 27 Oct 2026
Wave Life Sciences: Q3 Earnings Snapshot - kare11.com
Thu, 13 Aug 2026
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 197 (M) |
| Held by Insiders | 9.453e+007 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 16,280 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1452e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 248.3 % |
| Return on Equity (ttm) | -33.6 % |
| Qtrly Rev. Growth | 6.537e+007 % |
| Gross Profit (p.s.) | -0.62 |
| Sales Per Share | 0.37 |
| EBITDA (p.s.) | -1.01 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -192 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 9.61 |
| Price to Cash Flow | -2.19 |
| Dividend | 0 |
| Forward Dividend | 1.856e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|